α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?

Research output: Contribution to journalArticle

Abstract

Of the human solid cancers, Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM) display a natural history supporting the concept that they develop from multiple preneoplastic pathways. Recently, new evidence suggested that nicotinic Acetylcholine Receptors (nAChRs) play a significant role in lung cancer predisposition and natural history. This review is based on some translational research aimed at evaluating the potential therapeutic effect of nAChR antagonists on NSCLC and MPM. The background and rationale of this approach are based on the experimental observations that: (a) NSCLC and MPM cells express nAChRs and (b) the activation of these receptors by agonists, namely nicotine, inhibits apoptosis, whereas receptor antagonists have a pro-apoptotic effect.

Original languageEnglish
Pages (from-to)822-836
Number of pages15
JournalDrug Discovery Today
Volume14
Issue number17-18
DOIs
Publication statusPublished - Sep 2009

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?'. Together they form a unique fingerprint.

  • Cite this